Referencias

1. O'Connor FG, Deuster PA. Rhabdomyolysis. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 114.
2. Banzo J, Pérez J, Abós MD, Amores B, Prats E, García F, et al. Gammagrafía con 99mTc-MDP en rabdomiolisis. Rev Esp Med Nucl 2000;19:309-10.
3. Buja LM, Tofe AJ, Kulkarni PV, Mukherfee A, Parkey RW, Francis MD, et al. Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest 1977;60:724-40.
4. Kornhuber J, Weller M, Riederer P: Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect 1993;6:63-72.
5. Meterissian GB. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 1996;41:52-4.
6. Colectivo de Autores. Manual del Residente de Psiquiatría. Tomo II. p 1768-9. Litofinter, S.A. Madrid 1997.
7. Gutierrez I, Obon B, Villanueva B, Montoiro R, Moragrega B. Rabdomiolisis de origen multifactorial en paciente con intoxicación acuosa. Rev Toxicol 2006;23:154-5.
8. Blair RJ, Schroeder ET, McAfee JG, Duxbury CE. Skeletal muscle uptake of bone seeking agents in both traumatic and non traumatic rhabdomyolysis with acute renal failure. J Nucl Med 1975;16:515–6.
9. Sagar VV, Meckelnburg RL, Chaikin HL. Bone scan in rhabdomyolysis. Clin Nucl Med 1980;5:321–2.